Aquestive Therapeutics (AQST) Invested Capital (2017 - 2025)
Historic Invested Capital for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $2.2 million.
- Aquestive Therapeutics' Invested Capital rose 62809.52% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 62809.52%. This contributed to the annual value of -$15.2 million for FY2024, which is 7535.09% up from last year.
- According to the latest figures from Q3 2025, Aquestive Therapeutics' Invested Capital is $2.2 million, which was up 62809.52% from -$69.4 million recorded in Q2 2025.
- Over the past 5 years, Aquestive Therapeutics' Invested Capital peaked at $9.5 million during Q2 2024, and registered a low of -$98.3 million during Q3 2023.
- For the 5-year period, Aquestive Therapeutics' Invested Capital averaged around -$54.1 million, with its median value being -$61.5 million (2023).
- Data for Aquestive Therapeutics' Invested Capital shows a peak YoY increase of 62809.52% (in 2025) and a maximum YoY decrease of 82905.16% (in 2025) over the last 5 years.
- Quarter analysis of 5 years shows Aquestive Therapeutics' Invested Capital stood at -$80.1 million in 2021, then rose by 16.3% to -$67.1 million in 2022, then grew by 8.3% to -$61.5 million in 2023, then surged by 75.35% to -$15.2 million in 2024, then surged by 114.63% to $2.2 million in 2025.
- Its last three reported values are $2.2 million in Q3 2025, -$69.4 million for Q2 2025, and -$60.9 million during Q1 2025.